Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
13.02.2022
Medicines
Industry development
13.02.2022
The Rossiya 1 TV channel broadcast a report on a new drug against coronavirus infection, the antiviral drug Esperavir®, which contains molnupiravir.
Coronavirus infection is becoming manageable. Today, in addition to vaccines, targeted antiviral drugs have appeared. Molnupiravir is coming off the assembly line at the Biochemist plant in Saransk.
"The principle of action of the drug is that it blocks the enzyme by which the virus multiplies. It has its own unique targets in this enzyme. He copes with the virus in just five days," said Peter Bely, Chairman of the Board of Directors of Promomed Group.
The principle of action of molnupiravir is that it introduces errors into the genetic code of the virus, thereby preventing it from reproducing.
"When a virus enters the body and attaches to a cell, it penetrates into it and begins to multiply. Molnupiravir is aimed at interrupting this reproduction process as early as possible," says Natalia Selezneva, head of the Center for Advanced Training of Doctors and Retraining of Specialists, associate Professor at the Ogarev Moscow State University Medical Institute.
The development of this drug was simultaneously carried out by Russian scientists, the British and the Americans. The United States was the first to register this drug at the end of November last year. They were sold to Russia at limited quotas and inflated prices.
There has already been a similar deal in history. In the war of 1944, the Americans supplied the Soviet Union with penicillin for 4 dollars 40 cents per ampoule. Then it was decided to build seven plants for the production of a domestic antibiotic. And the modern Biochemist plant has become one of those enterprises.
In 1969, an advertising sign was displayed in the center of Paris: "The world's best Russian penicillin is manufactured at a medical drug factory in Saransk!" Now this plant produces a drug for the treatment of COVID-19 — molnupiravir.
"Its advantage is its good portability. That it can be used even if we are not sure if it is a coronavirus infection. And we see symptoms common to any respiratory viral infection: cough, runny nose, malaise, sore throat," said Larisa Bykova, Head of the Department of Pediatrics at Ogarev Mordovian State University, Corresponding Member of the Russian Academy of Sciences.
Sources
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
